Galvan C, Flores A, Cerrillos V, Avila I, Murphy C, Zheng W, To T T, Christofk H R, Lowry W E
bioRxiv. 2023 Oct 19:2023.10.16.562128. doi: 10.1101/2023.10.16.562128.
Among the numerous changes associated with the transformation to cancer, cellular metabolism is one of the first discovered and most prominent[1, 2]. However, despite the knowledge that nearly every cancer is associated with the strong upregulation of various metabolic pathways, there has yet to be much clinical progress on the treatment of cancer by targeting a single metabolic enzyme directly[3-6]. We previously showed that inhibition of glycolysis through lactate dehydrogenase (LDHA) deletion in cancer cells of origin had no effect on the initiation or progression of cutaneous squamous cell carcinoma[7], suggesting that these cancers are metabolically flexible enough to produce the necessary metabolites required for sustained growth in the absence of glycolysis. Here we focused on glutaminolysis, another metabolic pathway frequently implicated as important for tumorigenesis in correlative studies. We genetically blocked glutaminolysis through glutaminase (GLS) deletion in cancer cells of origin, and found that this had little effect on tumorigenesis, similar to what we previously showed for blocking glycolysis. Tumors with genetic deletion of glutaminolysis instead upregulated lactate consumption and utilization for the TCA cycle, providing further evidence of metabolic flexibility. We also found that the metabolic flexibility observed upon inhibition of glycolysis or glutaminolysis is due to post-transcriptional changes in the levels of plasma membrane lactate and glutamine transporters. To define the limits of metabolic flexibility in cancer initiating hair follicle stem cells, we genetically blocked both glycolysis and glutaminolysis simultaneously and found that frank carcinoma was not compatible with abrogation of both of these carbon utilization pathways. These data point towards metabolic flexibility mediated by regulation of nutrient consumption, and suggest that treatment of cancer through metabolic manipulation will require multiple interventions on distinct pathways.
在与癌症转变相关的众多变化中,细胞代谢是最早被发现且最为显著的变化之一[1,2]。然而,尽管已知几乎每种癌症都与各种代谢途径的强烈上调有关,但直接针对单一代谢酶进行癌症治疗在临床上尚未取得太多进展[3-6]。我们之前表明,通过缺失起源癌细胞中的乳酸脱氢酶(LDHA)来抑制糖酵解,对皮肤鳞状细胞癌的起始或进展没有影响[7],这表明这些癌症在代谢上具有足够的灵活性,能够在没有糖酵解的情况下产生持续生长所需的必要代谢物。在这里,我们聚焦于谷氨酰胺分解代谢,这是另一种在相关性研究中经常被认为对肿瘤发生很重要的代谢途径。我们通过在起源癌细胞中缺失谷氨酰胺酶(GLS)来基因阻断谷氨酰胺分解代谢,发现这对肿瘤发生影响很小,这与我们之前阻断糖酵解的结果相似。谷氨酰胺分解代谢基因缺失的肿瘤反而上调了乳酸的消耗以及用于三羧酸循环的利用率,这进一步证明了代谢灵活性。我们还发现,在抑制糖酵解或谷氨酰胺分解代谢时观察到的代谢灵活性是由于质膜乳酸和谷氨酰胺转运蛋白水平的转录后变化所致。为了确定癌症起始毛囊干细胞中代谢灵活性的限度,我们同时基因阻断了糖酵解和谷氨酰胺分解代谢,发现完全的癌症与这两种碳利用途径的废除是不相容的。这些数据指向了由营养物质消耗调节介导的代谢灵活性,并表明通过代谢操纵来治疗癌症将需要对不同途径进行多种干预。